Patients receiving big discounts for paying in cash

More and more patients have started paying for healthcare procedures in cash in exchange for significant discounts.

A recent story in the Wall Street Journal examined this trend, providing numerous examples of patients saving more than $500 on procedures by simply paying in cash up front instead of going through insurance.

“Not long ago, hospitals routinely charged uninsured patients their highest rates, far more than insured patients paid for the same services,” the article explained. “Now, in the Alice-in-Wonderland world of health-care prices, the opposite is often true: Patients who pay up front in cash often get better deals than their insurance plans have negotiated for them.”

According to WSJ reporting, some providers are keeping their cash-only rates as quiet as possible, because insurers could potentially find out and get upset. Meanwhile, other providers are happy to compete and have no problem sharing their discounts with the world.

“Patients have the right under federal law to request that we not bill their insurance,” Bill Munson, Boulder Community Hospital chief financial officer, said, as quoted in the article. “And when they do, they have the right to participate in our self-pay program.”

Click below to read the full story:

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.